Nishimori Isao, Tamakoshi Akiko, Kawa Shigeyuki, Tanaka Shigeki, Takeuchi Kazuo, Kamisawa Terumi, Saisho Hiromitsu, Hirano Kenji, Okamura Keiya, Yanagawa Nobuyuki, Otsuki Makoto
Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi, Japan.
Pancreas. 2006 Apr;32(3):244-8. doi: 10.1097/01.mpa.0000202950.02988.07.
The aim of this study was to estimate the number of autoimmune pancreatitis (AIP) patients in Japan and evaluate the influence of steroid therapy on the course of diabetes mellitus (DM) in AIP.
A total of 2972 departments were randomly selected with hospital stratification throughout Japan. We sent a questionnaire asking the selected departments to report the number of patients who had visited their hospital in 2002 and who fulfilled the diagnostic criteria for AIP set by the Japan Pancreas Society. We then sent a second questionnaire asking for the details of the clinical course of DM, if any, and the treatments used for AIP.
The annual number of AIP in Japan was estimated as approximately 900 (95% confidence interval 670-1100) or 0.71 per 100,000 individuals in the Japanese population. In the second survey, 66.5% of the 167 patients of AIP were reported as being complicated with DM. Among the AIP patients with DM (n = 93), 52% of the patients started to show DM simultaneously with the onset of AIP, and 33% of the patients had DM before the onset of AIP. Following steroid therapy, 55% and 36% of these patient groups showed improvement of DM control, respectively. On the other hand, less than 20% of patients showed newly developed DM or showed exacerbation of DM control after steroid therapy. The older the patients were, the higher were the rates of new development or exacerbation of DM.
These findings indicated that steroid therapy has a beneficial effect on the clinical courses of DM in approximately half of AIP patients. However, it also has negative effect on glucose tolerance in some patients, particularly older patients, and thus, careful observation for involvement of DM should be required in AIP patients treated with steroids.
本研究旨在估算日本自身免疫性胰腺炎(AIP)患者的数量,并评估类固醇疗法对AIP患者糖尿病(DM)病程的影响。
在日本全国范围内,按照医院分层随机选取了2972个科室。我们发送了一份调查问卷,要求被选中的科室报告2002年就诊且符合日本胰腺学会制定的AIP诊断标准的患者数量。随后,我们又发送了一份调查问卷,询问DM临床病程的详细情况(若有)以及AIP所采用的治疗方法。
据估计,日本AIP的年发病数约为900例(95%置信区间为670 - 1100),即每10万日本人口中有0.71例。在第二次调查中,167例AIP患者中有66.5%报告合并DM。在合并DM的AIP患者(n = 93)中,52%的患者DM与AIP同时发病,33%的患者在AIP发病前就已患有DM。类固醇治疗后,这两组患者中分别有55%和36%的患者DM控制情况得到改善。另一方面,不到20%的患者在类固醇治疗后出现新发DM或DM控制情况恶化。患者年龄越大,DM新发或恶化的发生率越高。
这些发现表明,类固醇疗法对大约一半的AIP患者的DM临床病程有有益影响。然而,它对一些患者,尤其是老年患者的糖耐量也有负面影响,因此,在接受类固醇治疗的AIP患者中,应仔细观察DM的情况。